FHA
HZNP

Flagship Harbor Advisors’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Flagship Harbor Advisors’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-1,200
Closed -$23K – 2013
2018
Q4 		$23K Hold
1,200
– – 0.01% 969
2018
Q3 		$23K Hold
1,200
– – ﹤0.01% 1072
2018
Q2 		$19K Buy
+1,200
New +$18.3K ﹤0.01% 1134

Other funds holding HZNP

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Scopia Capital Management New York $112M AUM 48.41% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Flagship Harbor Advisors's HZNP Position: Q1 2019 in Review

Flagship Harbor Advisors sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q1 2019, closing a stake of 1,200 shares — an estimated $23K sold.

Flagship Harbor Advisors first reported a position in HZNP in Q2 2018 and held it in 3 quarters. The position peaked at $23K in Q4 2018. 297 funds tracked by Wall St. Rank hold HZNP as of Q1 2019.

  • Flagship Harbor Advisors reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q1 2019 after selling out during the quarter.
  • Flagship Harbor Advisors sold 1,200 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q1 2019, an estimated $23K.
  • Flagship Harbor Advisors first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q2 2018 and held it in 3 quarters.
  • Flagship Harbor Advisors's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $23K in Q4 2018.
  • 297 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q1 2019.

Based on Flagship Harbor Advisors's 13F filing for Q1 2019, filed 15 Apr 2019.